No profile data available.
Royalty Pharma plc (RPRX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in New York, United States, with about 100 full-time employees.
It reported revenue of $2.38 billion for fiscal year 2025, up 5.1% from fiscal year 2024, and net income of $770.95 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $674.14 million, up 16.5% from a year before. Its market capitalization was $32.90 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Royalty Pharma reported $2.38 billion in revenue for fiscal year 2025, up 5.1% from $2.26 billion in fiscal year 2024. In Q2 2026 revenue was $674.14 million.
$32.90 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Takeda Pharmaceutical Company Limited (TAK), Teva Pharmaceutical Industries Limited (TEVA), Haleon plc (HLN), Viatris Inc. (VTRS).